As of 2026-09-15, the Relative Valuation of Tarsus Pharmaceuticals, Inc. (TARS) is (14.26) USD. This relative valuation is based on P/E multiples. With the latest stock price at 79.95 USD, the upside of Tarsus Pharmaceuticals, Inc. based on Relative Valuation is -117.8%.
The range of the Relative Valuation is (9.12) - (19.25) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 8.4x - 20.7x | 13.0x |
| Forward P/E multiples | 8.4x - 17.8x | 13.4x |
| Fair Price | (9.12) - (19.25) | (14.26) |
| Upside | -111.4% - -124.1% | -117.8% |
| Date | P/E |
| 2026-09-11 | -73.41 |
| 2026-09-10 | -75.09 |
| 2026-09-09 | -76.62 |
| 2026-09-08 | -80.73 |
| 2026-09-04 | -84.03 |
| 2026-09-03 | -77.02 |
| 2026-09-02 | -76.61 |
| 2026-09-01 | -68.54 |
| 2026-08-31 | -68.72 |
| 2026-08-28 | -66.42 |
| 2026-08-27 | -66.57 |
| 2026-08-26 | -65.40 |
| 2026-08-25 | -66.14 |
| 2026-08-24 | -67.40 |
| 2026-08-21 | -67.29 |
| 2026-08-20 | -66.17 |
| 2026-08-19 | -67.98 |
| 2026-08-18 | -65.75 |
| 2026-08-17 | -65.36 |
| 2026-08-14 | -64.05 |
| 2026-08-13 | -63.76 |
| 2026-08-12 | -64.81 |
| 2026-08-11 | -64.29 |
| 2026-08-10 | -62.72 |
| 2026-08-07 | -59.97 |
| 2026-08-06 | -60.47 |
| 2026-08-05 | -56.73 |
| 2026-08-04 | -56.57 |
| 2026-08-03 | -56.76 |
| 2026-07-31 | -54.65 |
| 2026-07-30 | -55.11 |
| 2026-07-29 | -54.17 |
| 2026-07-28 | -54.57 |
| 2026-07-27 | -55.65 |
| 2026-07-24 | -54.30 |
| 2026-07-23 | -54.22 |
| 2026-07-22 | -53.30 |
| 2026-07-21 | -53.00 |
| 2026-07-20 | -52.07 |
| 2026-07-17 | -55.40 |
| 2026-07-16 | -53.40 |
| 2026-07-15 | -53.22 |
| 2026-07-14 | -51.94 |
| 2026-07-13 | -54.90 |
| 2026-07-10 | -53.82 |
| 2026-07-09 | -59.37 |
| 2026-07-08 | -62.69 |
| 2026-07-07 | -65.30 |
| 2026-07-06 | -62.06 |
| 2026-07-02 | -60.57 |